| Market Cap | 17.02M | P/E | - | EPS this Y | 30.90% | Ern Qtrly Grth | - |
| Income | -18.28M | Forward P/E | -2.55 | EPS next Y | -11.80% | 50D Avg Chg | 1.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -5.00% |
| Dividend | N/A | Price/Book | 0.86 | EPS next 5Y | - | 52W High Chg | -87.00% |
| Recommedations | 3.00 | Quick Ratio | 0.43 | Shares Outstanding | 18.90M | 52W Low Chg | 46.00% |
| Insider Own | 17.69% | ROA | -30.22% | Shares Float | 13.90M | Beta | - |
| Inst Own | 23.45% | ROE | -101.63% | Shares Shorted/Prior | 23.33K/60.34K | Price | 1.07 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,081,720 | Target Price | 9.00 |
| Oper. Margin | - | Earnings Date | Mar 9 | Volume | 67,562 | Change | -1.83% |
Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.